268 related articles for article (PubMed ID: 23568455)
1. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.
Baiz D; Pinder TA; Hassan S; Karpova Y; Salsbury F; Welker ME; Kulik G
J Med Chem; 2012 Sep; 55(18):8038-46. PubMed ID: 22924393
[TBL] [Abstract][Full Text] [Related]
4. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Garlich JR; De P; Dey N; Su JD; Peng X; Miller A; Murali R; Lu Y; Mills GB; Kundra V; Shu HK; Peng Q; Durden DL
Cancer Res; 2008 Jan; 68(1):206-15. PubMed ID: 18172313
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
Morales GA; Garlich JR; Su J; Peng X; Newblom J; Weber K; Durden DL
J Med Chem; 2013 Mar; 56(5):1922-39. PubMed ID: 23410005
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Okada M; Ohta M; Tsukamoto S; Parker P; Workman P; Waterfield M
Bioorg Med Chem; 2006 Oct; 14(20):6847-58. PubMed ID: 16837202
[TBL] [Abstract][Full Text] [Related]
7. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
8. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα.
Yin Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
Eur J Med Chem; 2019 Nov; 182():111630. PubMed ID: 31446244
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents.
Amin KM; Eissa AA; Abou-Seri SM; Awadallah FM; Hassan GS
Eur J Med Chem; 2013 Feb; 60():187-98. PubMed ID: 23291120
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors.
Parveen I; Khan P; Ali S; Hassan MI; Ahmed N
Eur J Med Chem; 2018 Nov; 159():166-177. PubMed ID: 30290280
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
Guo J; Wang T; Wu T; Zhang K; Yin W; Zhu M; Pang Y; Hao C; He Z; Cheng M; Liu Y; Zheng J; Gu J; Zhao D
Eur J Med Chem; 2020 Jan; 186():111878. PubMed ID: 31757524
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
13. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
14. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
[TBL] [Abstract][Full Text] [Related]
15. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
Bielec B; Schueffl H; Terenzi A; Berger W; Heffeter P; Keppler BK; Kowol CR
Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
[TBL] [Abstract][Full Text] [Related]
17. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
Rewcastle GW; Gamage SA; Flanagan JU; Kendall JD; Denny WA; Baguley BC; Buchanan CM; Chao M; Kestell P; Kolekar S; Lee WJ; Lill CL; Malik A; Singh R; Jamieson SM; Shepherd PR
Eur J Med Chem; 2013 Jun; 64():137-47. PubMed ID: 23644197
[TBL] [Abstract][Full Text] [Related]
19. The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells.
Guney Eskiler G
J Pharm Pharm Sci; 2019; 22(1):599-611. PubMed ID: 31804921
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological explorations of eco-friendly amide substituted (Z)-β-enaminones as anti-breast cancer drugs.
Subramamiam P; Ramasubbu C; Athiramu S; Arumugam S; Alagumuthu M
Arch Pharm (Weinheim); 2019 Jan; 352(1):e1800244. PubMed ID: 30515835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
